No Detail Found!

Simple UV Spectrophotometric Method Development for Determination of Meropenem in Bulk Form.

Author(s)
Saima Asif Drug Regulatory Authority Government of Pakistan
Saima Asif Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Tanweer Alam Drug Regulatory Authority Government of Pakistan, Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Amber Nawab Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Safila Naveed Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Abstract
The drug Meropenem was analyzed by using UV spectrophotometer. The quantification of the drug was achieved in the wavelength range of 200-400 nm at 298nm. The developed method was applied for rapid analysis of the bulk form. The value of Relative Standard Deviation were found to be within acceptable range of less than 2%. The parameters of validation- linearity, precision, accuracy, specificity, robustness, limit of detection and limit of quantitation were calculated according to International Conference on Harmonization guidelines. The UV spectrophotometric method was performed at 298 nm. The samples were prepared in water followed by the stability studies of meropenem in aqueous solution at 4, 25 and 40 degrees C along with acidic and alkaline conditions. The results were satisfactory with good stability after 24 h at 4 degrees C. The method was validated and demonstrated to be rugged. The limit of quantitation and the limit of detection were established as 0.187 and 0.569 respectively. The developed validated UV spectrophotometric method is potentially valuable for routine laboratory analysis because of its ease, simplicity, rapidness, sensitivity, precision and accuracy.
Publication Details
Page(s) 45-49
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 5, Issue: 1, Year: 2017

Request the full text from PASTIC

References
*K. J. Williamsb , G.,Vukmirovitsc , V.,Chmelikd , B.,Pfauslera, 1995.A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults,Journal of Antimicrobial Chemotherapy 36 85 -97
Garnacho-MonteroJ,Garcia-GarmendiaJL,BarreroAlmodovarA, 2003.Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis,Crit Care Med 31 2742 -51
KollefMH,ShermanG, .Inadequate antimicrobialtreatment of infections: a risk factor for hospital mortality among criti-cally ill patients,Chest1999 115 462 -74
KumarA,RobertsD, 2006.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock,Crit Care Med 34 1589 -96
DrusanoGL, 2004.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug',Nat Rev Microbiol 289 -300
AstraZeneca, 2007.Merrem (meropenem) package insert, -
KutiJL,MaglioD,NightingaleCH,NicolauDP, 2003.Economic Benefit of a Meropenem dosage strategy based on pharmacodynamic concepts,Am J Health-Syst Pharm 60 565 -8
Hurst , M.,and H. M.Lamb, 2000.Meropenem: a review of its use in patients in intensive care,Drugs 59 653 -680
KutiJL,MaglioD,NightingaleCH,NicolauDP, 2003.Economic Benefit of a Meropenem dosage strategy based on pharmacodynamic concepts,Am J Health-Syst Pharm 60 565 -8
Giles , L. J.,A. C.Jennings,A. H.Thomson,R. J.Beale,A.McLuckie, 2000.Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration,Crit. Care Med 28 632637 -
Krueger , W. A., T. H.,Schroeder , M.,Hutchison , E. Hoffmann, H. J.,Dieterich , A.,Heininger , C.,Erley , A.,Wehrle , and K.,Unertl, 1998.Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration,Antimicrob. Agents Chemother 42 2421 -2424
Thalhammer , F.,P.Schenk,H.Burgmann,I. ElMenyawi,U. M.Hollenstein,A. R.Rosenkranz,G.Sunder-Plassmann,S.Breyer,K.Ratheiser, 1998.Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration,Antimicrob. Agents Chemother 42 2417 -2420
Ververs , T. F.,A. van Dijk , S. A.,Vinks , P. J.,Blankestijn , J. F.,Savelkoul , J.,Meulenbelt , and F. T.,Boereboom, 2000.Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration,Crit. Care Med 37 2071 -2078
Roberts , J. A.,S.Webb,D.Paterson,K.,US EPA; Estimation Program Interface M. Ho , and J.,Lipman,Jan, 2012.Available review on clinical benefits of continuous from,as of Jan 25 4 -
0

Citations

0

Downloads

43

Views